For: | Novillo A, Gaibar M, Romero-Lorca A, Gilsanz MF, Beltrán L, Galán M, Antón B, Malón D, Moreno A, Fernández-Santander A. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World J Gastroenterol 2020; 26(16): 1979-1986 [PMID: 32390708 DOI: 10.3748/wjg.v26.i16.1979] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v26/i16/1979.htm |
Number | Citing Articles |
1 |
Benny Mosoane, Georgios Lolas, Zodwa Dlamini. Colorectal Cancer Treatment Resistance. 2025; : 25 doi: 10.1016/B978-0-443-33475-7.00014-7
|
2 |
Mauri Dobbs Spendlove, Trenton M. Gibson, Shaney McCain, Benjamin C. Stone, Tristan Gill, Brett E. Pickett. Pathway2Targets: an open-source pathway-based approach to repurpose therapeutic drugs and prioritize human targets. PeerJ 2023; 11: e16088 doi: 10.7717/peerj.16088
|
3 |
Ahmed M. Kabel, Ahmed M. Ashour, Dina A. Ali, Hany H. Arab. The immunomodulatory effects of topiramate on azoxymethane-induced colon carcinogenesis in rats: The role of the inflammatory cascade, vascular endothelial growth factor, AKT/mTOR/MAP kinase signaling and the apoptotic markers. International Immunopharmacology 2021; 98: 107830 doi: 10.1016/j.intimp.2021.107830
|
4 |
Dong-Sheng Sun, Cang-Hai Guan, Wei-Na Wang, Zeng-Tao Hu, Yu-Qiao Zhao, Xing-Ming Jiang. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis. Microvascular Research 2021; 134: 104120 doi: 10.1016/j.mvr.2020.104120
|
5 |
María Gaibar, Miguel Galán, Alicia Romero-Lorca, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander, Apolonia Novillo. Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences 2021; 22(3): 1381 doi: 10.3390/ijms22031381
|
6 |
Monika Zajkowska, Maciej Dulewicz, Agnieszka Kulczyńska-Przybik, Kamil Safiejko, Marcin Juchimiuk, Marzena Konopko, Leszek Kozłowski, Barbara Mroczko. CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-45093-4
|
7 |
Lara J. Bou Malhab, Maha M. Saber-Ayad, Ranyah Al-Hakm, Vidhya A. Nair, Panagiotis Paliogiannis, Gianfranco Pintus, Wael M. Abdel-Rahman. Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation. Current Pharmaceutical Design 2021; 27(18): 2156 doi: 10.2174/1381612827666210303143442
|
8 |
Amina T. Mneimneh, Nadine Darwiche, Mohammed M. Mehanna. Investigating the therapeutic promise of drug-repurposed-loaded nanocarriers: A pioneering strategy in advancing colorectal cancer treatment. International Journal of Pharmaceutics 2024; 664: 124473 doi: 10.1016/j.ijpharm.2024.124473
|
9 |
|
10 |
Mehtap Cevik, Esat Namal, Nur Dinc-Sener, Ulkuhan Iner-Koksal, Cavlan Ciftci, Belgin Susleyici. Investigation of Vascular Endothelial Growth Factor Polymorphisms on Risk, Metastasis, Laterality, and Prognosis of Colorectal Cancer in Turkish Subjects. Genetic Testing and Molecular Biomarkers 2022; 26(5): 298 doi: 10.1089/gtmb.2021.0213
|